2022 Annual Report and Notice of AGM

RNS Number : 4693V
Hutchmed (China) Limited
11 April 2023
 

 

 

2022 Annual Report and Notice of Annual General Meeting

 

Hong Kong, Shanghai, & Florham Park, NJ - Tuesday, April 11, 2023: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2022 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy ("AGM Materials") will be posted to shareholders on April 12, 2023 who have elected to receive the AGM Materials in printed form. The documents can also be accessed from the HUTCHMED website (www.hutch-med.com).

 

The 2023 Annual General Meeting ("AGM") will be an electronic/hybrid meeting to be held at 1st Floor, Harbour Grand Kowloon, 20 Tak Fung Street, Hung Hom, Kowloon, Hong Kong on Friday, May 12, 2023 at 5:00 pm Hong Kong Time (10:00 am London Time), with online access through an online platform as detailed in the AGM Materials.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

 

CONTACTS

Investor Enquiries


Mark Lee, Senior Vice President

+852   2121   8200

Annie Cheng, Vice President

+1   (973)   306 4490



Media Enquiries

 

Americas - Brad Miles,
Solebury Trout

+1   (917)   570   7340   (Mobile) 
bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw,
FTI Consulting

+44   20   3727   1030 / +44   7771   913   902   (Mobile) / +44 7779 545 055 (Mobile)
HUTCHMED@fticonsulting.com

Asia - Zhou Yi,
Brunswick

+852   97 83   6894   (Mobile)
HUTCHMED@brunswickgroup.com



Nominated Advisor


Atholl Tweedie / Freddy Crossley, Panmure Gordon

+44   (20)   7886   2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAFIFSTSAIEIIV
UK 100

Latest directors dealings